54.68
-1.925(-3.40%)
Currency In USD
| Previous Close | 56.6 |
| Open | 56.85 |
| Day High | 56.89 |
| Day Low | 54.44 |
| 52-Week High | 58.93 |
| 52-Week Low | 19.45 |
| Volume | 799,255 |
| Average Volume | 720,922 |
| Market Cap | 3.91B |
| PE | -15.06 |
| EPS | -3.63 |
| Moving Average 50 Days | 45.15 |
| Moving Average 200 Days | 38.93 |
| Change | -1.93 |
If you invested $1000 in Kymera Therapeutics, Inc. (KYMR) since IPO date, it would be worth $1,643.87 as of October 01, 2025 at a share price of $54.675. Whereas If you bought $1000 worth of Kymera Therapeutics, Inc. (KYMR) shares 3 years ago, it would be worth $2,608.54 as of October 01, 2025 at a share price of $54.675.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses
GlobeNewswire Inc.
Sep 17, 2025 11:00 AM GMT
Featured presentations showcase the positive Phase 1 healthy volunteer trial results supporting KT-621’s oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25
Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary
GlobeNewswire Inc.
Sep 03, 2025 11:00 AM GMT
WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced th
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire Inc.
Aug 27, 2025 11:00 AM GMT
WATERTOWN, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced tha